EMA accepts Sanofi's Toujeo for review

Sanofi (Euronext:SAN; NYSE:SNY) said EMA accepted for review an MAA for Toujeo (formerly U300) to treat Type I and Type II diabetes. Toujeo is a 300 units/mL formulation of insulin glargine, a synthet...